New medicinal use of nintedanib, and derivative and medicinal salt thereof

A technology of nintedanib and derivatives, which is applied in the field of pharmaceutical applications to achieve strong pharmacological effects, good safety, and the effects of improving treatment and prognosis

Pending Publication Date: 2021-06-18
CANCER INST & HOSPITAL CHINESE ACADEMY OF MEDICAL SCI
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] At present, there are no research reports on the use of nintedanib, its derivatives or medicinal salts in the prevention and / or treatment of peritoneal adhesions at home and abroad

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • New medicinal use of nintedanib, and derivative and medicinal salt thereof
  • New medicinal use of nintedanib, and derivative and medicinal salt thereof
  • New medicinal use of nintedanib, and derivative and medicinal salt thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0028] Example 1: Animal experiments on the preventive and therapeutic effects of nintedanib on a rat model of peritoneal adhesions

[0029] 1. Experimental materials

[0030] 1.1 Experimental animals: 18 SD rats (SPF grade, female, 220g-260g), source and animal qualification certificate: Beijing Huafukang Biotechnology Co., Ltd.; SCXK (Beijing) 2019-0008, NO.1103221911015030.

[0031] 1.2 Reagent: Chloral, hydrate: C804539, Shanghai Macklin Biochemical Company; 10% chloral hydrate: use material 2) and pure water to prepare 10% chloral hydrate solution; iodophor disinfectant: batch number 200528W, Changjiang, Beijing Mai Medicine Technology Co., Ltd.; Nintedanib (purity 99.97%): Item No.: HY-50904, MedChemExpress (MCE) Company; Medical 0.9% Sodium Chloride Solution (Normal Saline): Batch No.: C202005121, China Resources Double-Crane Pharmaceuticals limited company.

[0032] 1.3 Equipment: surgical instruments: tissue scissors (J22010, Shanghai Medical Instrument (Group) Co.,...

Embodiment 2

[0050] Example 2: Pathological evaluation experiment of nintedanib on local inflammatory response and fibrosis response of peritoneal adhesion tissue in rats

[0051] 1. Experimental materials

[0052] 1.1 Source of pathological tissue: ischemic nodular tissue and peritoneal adhesion tissue of experimental rat abdominal wall in rat peritoneal adhesion experiment

[0053] 1.2 Reagent: 10% Neutral Formalin Fixative: Item No.: Top0372, Beijing Biotuoda Technology Co., Ltd.; Medical 0.9% Sodium Chloride Solution (Normal Saline): Batch No.: C202005121, China Resources Double Crane Pharmaceutical Co., Ltd. ; Anhydrous ethanol solution (for molecular biology): Product No.: E111991, Shanghai Aladdin Biochemical Technology Co., Ltd.; Xylene solution: Product No.: 1330-20-7, Sinopharm Chemical Reagent Co., Ltd.; hematoxylin-eosin Staining kit (H&E Staining kit): product number: ab245880, Abcam, USA.

[0054] 1.3 Equipment: Leica manual rotary pathological slicer: Model: RM2235, Leica ...

Embodiment 3

[0067] Embodiment three: the preparation of nintedanib tablet

[0068] Take 100g of nintedanib, mix it with conventional adjuvants, and prepare 1000 nintedanib tablets according to conventional methods to obtain nintedanib tablets with a specification of 100 mg.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Diameteraaaaaaaaaa
Login to view more

Abstract

The invention relates to new medicinal use of nintedanib, and a derivative and a medicinal salt thereof, in particular to the use in preparing a medicine for preventing and / or treating peritoneal adhesion. Animal experiment results show that the nintedanib can significantly reduce the occurrence of the peritoneal adhesion after abdominal surgery of rats, improve the texture of the peritoneal adhesion, reduce the toughness of the peritoneal adhesion, and reduce an inflammation and fibrosis degree of peritoneal tissues. An important theoretical basis for the use of the nintedanib, and the derivative or the medicinal salt thereof in treating peritoneal adhesion is provided, a treatment range of the medicine is widened, and meanwhile a new medicine solution for treating the peritoneal adhesion is provided.

Description

technical field [0001] The invention belongs to the technical field of pharmaceutical application, and specifically relates to the new application of nintedanib, its derivatives or pharmaceutically acceptable salts. Background technique [0002] Peritoneal adhesion is a common complication of abdominal and pelvic surgery, and its incidence rate can be as high as 90%. It is an important problem that has plagued the field of clinical diagnosis and treatment for a long time. Peritoneal adhesions can lead to many serious complications, including intestinal obstruction, infertility, chronic abdominal and pelvic pain, etc., which seriously affect the health and quality of life of patients. More than 20% of patients with peritoneal adhesions will need to be re-admitted to the hospital for adhesiolysis and other treatments due to symptoms such as intestinal obstruction, but the recurrence rate of peritoneal adhesions after surgery is still high, which not only increases the burden o...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/496A61P41/00
CPCA61K31/496A61P41/00
Inventor 符艳龚涛李肖曹家玮赵赫张晓武李金贵
Owner CANCER INST & HOSPITAL CHINESE ACADEMY OF MEDICAL SCI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap